Fig. 7 | Nature Communications

Fig. 7

From: Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease

Fig. 7The alternative text for this image may have been generated using AI.

Higher abundance of tyrosine decarboxylase can explain increased levodopa administration requirement in Parkinson’s disease patients. A model representing two opposing situations, in which the proximal small intestine is colonized by low (left) or high abundance of tyrosine decarboxylase-encoding bacteria. The latter could result from or lead to increased individual L-DOPA dosage intake

Back to article page